Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43865   clinical trials with a EudraCT protocol, of which   7286   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2017-001772-28
    Sponsor's Protocol Code Number:PAC203
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2020-12-15
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2017-001772-28
    A.3Full title of the trial
    An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients with Thrombocytopenia and Primary Myelofibrosis, Post- Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Previously Treated with Ruxolitinib
    Studio di fase 2, in aperto, randomizzato, di determinazione della dose di pacritinib in pazienti affetti da trombocitopenia e mielofibrosi primaria, mielofibrosi post-policitemia vera o mielofibrosi post-trombocitemia essenziale precedentemente trattati con ruxolitinib
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A Phase 2 Dose-Finding Study of Pacritinib in Myelofibrosis Patients
    Studio di fase 2 di determinazione della dose in pazienti con mielofibrosi
    A.3.2Name or abbreviated title of the trial where available
    NA
    NA
    A.4.1Sponsor's protocol code numberPAC203
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorCTI BIOPHARMA CORP.
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportCTI BioPharma Corp
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationCTI BioPharma Corp.
    B.5.2Functional name of contact pointRegulatory Affairs-Sarah H. Telzrow
    B.5.3 Address:
    B.5.3.1Street Address3101 Western Avenue, Suite 600
    B.5.3.2Town/ citySeattle
    B.5.3.3Post codeWA 98121
    B.5.3.4CountryUnited States
    B.5.4Telephone number0012062724426
    B.5.5Fax number0012062846206
    B.5.6E-mailstelzrow@ctibiopharma.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEU3-10-767-003, EU3-10-768- 003, EU3-10-769-003
    D.3 Description of the IMP
    D.3.1Product namePacritinib
    D.3.2Product code [Pacritinib]
    D.3.4Pharmaceutical form Capsule, hard
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNPACRITINIB
    D.3.9.1CAS number 937272-79-2
    D.3.9.2Current sponsor codeSB1518
    D.3.9.4EV Substance CodeSUB114513
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number100
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Primary Myelofibrosis, Post-essential thrombocythemia myelofibrosis,
    Post polycythaemia vera myelofibrosis
    mielofibrosi primaria, mielofibrosi post-policitemia vera o mielofibrosi post-trombocitemia essenziale
    E.1.1.1Medical condition in easily understood language
    Primary or Secondary Myelofibrosis (MF)
    Mielofibrosi Primaria o secondaria (mf)
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10028537
    E.1.2Term Myelofibrosis
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 21.1
    E.1.2Level LLT
    E.1.2Classification code 10074691
    E.1.2Term Post polycythaemia vera myelofibrosis
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10028537
    E.1.2Term Myelofibrosis
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 21.0
    E.1.2Level LLT
    E.1.2Classification code 10074692
    E.1.2Term Post essential thrombocythaemia myelofibrosis
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level SOC
    E.1.2Classification code 10029104
    E.1.2Term Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To determine a recommended dosage of pacritinib for further clinical studies
    Determinare un dosaggio raccomandato di pacritinib per ulteriori studi clinici
    E.2.2Secondary objectives of the trial
    1. To examine the dose¿response relationship for efficacy, as measured by spleen volume reduction
    (SVR) using magnetic resonance imaging (MRI) or computed tomography (CT) and total symptom
    score (TSS) using the MPN-SAF TSS 2.0
    2. To examine the dose¿response relationship for safety with a focus on adverse events (AE) of interest
    3. To further characterize the pharmacokinetics (PK) and pharmacodynamics (PD) of pacritinib
    1. Esaminare la correlazione dose¿risposta per l'efficacia, misurata dalla riduzione del volume splenico (Spleen Volume Reduction, SVR) mediante risonanza magnetica (RM) o tomografia computerizzata (TC) e dal punteggio dei sintomi totali (Total Symptom Score, TSS) usando l'MPN-SAF TSS 2.0
    2. Esaminare la correlazione dose¿risposta per la sicurezza concentrandosi sugli eventi avversi (Adverse event, AE) di interesse
    3. Caratterizzare ulteriormente la farmacocinetica (PK) e la farmacodinamica (PD) di pacritinib
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. PMF, PPV-MF, or PET-MF (as defined by Tefferi and Vardiman 2008)
    2. DIPSS Intermediate-1, Intermediate -2, or High risk (Passamonti et al 2010)
    3. Prior ruxolitinib treatment failure or intolerance as defined by:
    a. Treatment for =6 months with inadequate efficacy response (any measure) in the judgement of the investigator
    b. Treatment for =28 days complicated by either
    i. Red blood cell transfusion
    ii. National Cancer Institute (NCI) CTCAE grade =3 AEs of thrombocytopenia, anemia, hematoma, and/or hemorrhage while being treated with a dosage of <20 mg BID
    4. Palpable splenomegaly =5 cm below the lower costal margin in the midclavicular
    line as assessed by physical examination
    5. Platelet count of =100,000/µL at any time during the screening period and prior to
    first dose of pacritinib, including patients who are platelet transfusion-dependent
    6. TSS of =10 on the MPN-SAF TSS 2.0
    7. Age =18 years old
    8. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2
    9. Peripheral blast count of <10%
    10. Absolute neutrophil count of >500/µL
    11. Adequate liver and renal function, defined by liver transaminases (aspartate
    aminotransferase [AST]/serum glutamic oxaloacetic transaminase [SGOT] and
    alanine aminotransferase [ALT]/serum glutamic pyruvic transaminase [SGPT]),
    =3 × the u pper l imit o f n ormal ( ULN) ( AST/ALT = 5 × U LN i f t ransaminase
    elevation is related to MF), direct bilirubin =4× ULN, and creatinine =2.5 mg/dL
    12. Adequate coagulation function, defined by prothrombin time (PT)/international
    normalized ratio (INR), partial thromboplastin time (PTT), or thrombin time (TT) of
    =1.5 × ULN
    13. Left ventricular cardiac ejection fraction of =45% by echocardiogram or multigated
    acquisition (MUGA) scan
    14. QTc interval of <450 ms as assessed by ECG and corrected by the Fredericia method
    15. If fertile, willing to use effective birth control methods during the study
    16. Willing to undergo and able to tolerate frequent MRI or CT assessments during the
    study
    17. Able to understand and willing to complete symptom assessments using a
    patient-reported outcomes instrument
    18. Provision of informed consent
    1. PMF, PPV-MF o PET-MF (come definiti da Tefferi and Vardiman 2008)
    2. Rishio secondo DIPSS intermedio-1, intermedio-2 o elevato (Passamonti et al 2010)
    3. Precedente insuccesso del trattamento con ruxolitinib o intolleranza al trattamento, definiti da:
    a. trattamento per =6 mesi con risposta inadeguata per l'efficacia (qualsiasi misurazione) secondo il giudizio dello sperimentatore
    b. trattamento per =28 giorni con complicanze o per
    i. trasfusione di emazie
    ii. o AE riguardanti trombocitopenia, anemia, ematoma e/o emorragia di grado =3 secondo i criteri CTCAE del National Cancer Institute (NCI) durante il trattamento con una dose <20 mg BID
    4. Splenomegalia palpabile =5 cm sotto il margine costale inferiore nella linea medio-clavicolare, valutata mediante esame obiettivo
    5. Conta delle piastrine =100.000/µl in qualsiasi momento durante il periodo di screening e prima della prima dose di pacritinib, compresi i pazienti dipendenti da trasfusione di piastrine
    6. TSS =10 secondo l'MPN-SAF TSS 2.0
    7. Età =18 anni
    8. Stato di validità (Eastern Cooperative Oncology Group, ECOG) da 0 a 2
    9. Conta dei blasti periferici <10%
    10. Conta assoluta dei neutrofili >500/µl
    11. Funzionalità epatica e renale adeguata, definita da livelli di transaminasi epatiche (aspartato aminotransferasi [AST]/transaminasi glutammico-ossalacetica sierica [SGOT] e alanina aminotransferasi [ALT]/transaminasi glutammico-piruvica sierica [SGPT]), =3 × il limite superiore di normalità (ULN) (AST/ALT =5 × ULN se l'aumento delle transaminasi è correlato a MF), bilirubina diretta =4× ULN e creatinina =2,5 mg/dl
    12. Funzionalità della coagulazione adeguata, definita da tempo di protrombina (PT)/rapporto internazionale normalizzato (INR), tempo di tromboplastina parziale (PTT), o tempo di trombina (TT) =1,5 × ULN
    13. Frazione di eiezione cardiaca ventricolare sinistra =45% misurata con ecocardiogramma o scansione con acquisizione a gate multipli(MUGA)
    14. Intervallo QTc <450 ms valutato dall'ECG e corretto con il metodo Fredericia
    15. Se fertile, disponibilità a utilizzare metodi contraccettivi efficaci durante lo studio
    16. Disponibilità a sottoporsi a valutazioni RM o TC frequenti e capacità di tollerarle durante lo studio
    17. Capacità di comprendere e disponibilità a compilare le valutazioni sui sintomi usando lo strumento degli esiti riferiti dal paziente
    18. Manifestazione del consenso informato firmato
    E.4Principal exclusion criteria
    1. Life expectancy <6 months
    2. Completed allogeneic stem cell transplant (ASCT) or are eligible for and willing to
    complete ASCT
    3. History of splenectomy or planning to undergo splenectomy
    4. Splenic irradiation within the last 6 months
    5. Previously treated with pacritinib
    6. Treatment with anticoagulation or antiplatelet agents, except for aspirin dosages of
    =100 mg per day, within the last 2 weeks
    7. Treatment with a potent cytochrome P450 (CYP450) inducer within the last 2 weeks
    8. Treatment with medications that can prolong the QTc interval within the last 2 weeks
    9. Significant recent bleeding history defined as NCI CTCAE grade =2 within the last
    3 months, unless precipitated by an inciting event (e.g., surgery, trauma, injury)
    10. Any history of CTCAE grade =2 non-dysrhythmia cardiac conditions within the last
    6 months. Patients with asymptomatic grade 2 non-dysrhythmia cardiac conditions
    may be considered for inclusion, with the approval of the medical monitor, if stable
    and unlikely to affect patient safety.
    11. New York Heart Association Class II, III, or IV congestive heart failure
    12. Any history of CTCAE grade =2 cardiac dysrhythmias within the last 6 months.
    Patients with non-QTc CTCAE grade 2 cardiac dysrhythmias may be considered for
    inclusion, with the approval of the medical monitor, if the dysrhythmias are stable, asymptomatic, and unlikely to affect patient safety.
    13. QTc prolongation >450 ms or other factors that increase the risk for QT interval
    prolongation (e.g., heart failure, hypokalemia [defined as serum potassium
    <3.0 mEq/L that is persistent and refractory to correction], family history of long QT
    interval syndrome, or concomitant use of medications that may prolong QT interval)
    14. Any gastrointestinal or metabolic condition that could interfere with absorption of
    oral medication
    15. Inflammatory or chronic functional bowel disorder such as Crohn’s Disease,
    inflammatory bowel disease, chronic diarrhea, or constipation
    16. Other malignancy within the last 3 years, other than curatively treated basal cell or
    squamous cell skin cancer, carcinoma in situ of the cervix, organ-confined or treated
    nonmetastatic prostate cancer with negative prostate-specific antigen, in situ breast
    carcinoma after complete surgical resection, or superficial transitional cell bladder
    carcinoma
    17. Uncontrolled intercurrent illness, including, but not limited to, ongoing active
    infection or psychiatric illness or social situation that, in the judgment of the treating
    physician, would limit compliance with study requirements
    18. Known seropositivity for human immunodeficiency virus
    19. Known active hepatitis A, B, or C virus infection
    20. Women who are pregnant or lactating
    1. Aspettativa di vita <6 mesi
    2. Pregresso trapianto allogenico di cellule staminali (Allogeneic Stem Cell Transplant, ASCT) o idoneità e disponibilità a sottoporsi al trapianto ASCT
    3. Anamnesi di splenectomia o splenectomia programmata
    4. Irradiazione splenica negli ultimi 6 mesi
    5. Precedentemente trattamento con pacritinib
    6. Trattamento con agenti anticoagulanti o antipiastrinici, eccetto aspirina a dosi =100 mg/die nelle 2 ultime settimane
    7. Trattamento con un induttore potente del citocromo P450 (CYP450) nelle ultime 2 settimane
    8. Trattamento con medicinali che possono prolungare l'intervallo QT nelle ultime 2 settimane
    9. Anamnesi di recente emorragia significativa di grado =2 secondo i criteri NCI CTCAE negli ultimi 3 mesi, se non dovuta a un evento provocatore (ad es., intervento chirurgico, trauma, lesione)
    10. Qualsiasi anamnesi di cardiopatia non disritmica di grado =2 secondo i criteri CTCAE negli ultimi 6 mesi. Pazienti affetti da cardiopatie non disritmiche di grado 2 possono essere valutati per l'inclusione, con l'approvazione del supervisore medico, se tali condizioni sono stabili e difficilmente influiranno sulla sicurezza del paziente.
    11. Insufficienza cardiaca congestizia di classe II, III o IV secondo la NYHA (New York Heart Association)
    12. Qualsiasi anamnesi di disritmia cardiaca di grado =2 secondo i criteri CTCAE negli ultimi 6 mesi. Pazienti affetti da disritmie cardiache di grado 2 (non QTc) possono essere valutati per l'inclusione, con l'approvazione del supervisore medico, se le disritmie sono stabili, asintomatiche e difficilmente influiranno sulla sicurezza del paziente.
    13. Prolungamento dell'intervallo QTc >450 ms o altri fattori che aumentano il rischio di prolungamento dell'intervallo QT (ad es., insufficienza cardiaca, ipokaliemia [definita da un livello di potassio sierico <3,0 mEq/l, persistente e refrattaria a correzione], anamnesi familiare di sindrome del QT lungo o uso concomitante di medicinali che possono prolungare l'intervallo QT)
    14. Qualsiasi condizione gastrointestinale o metabolica che potrebbe interferire con l'assorbimento di medicinali orali
    15. Disturbi funzionali intestinali infiammatori o cronici, quali morbo di Crohn, malattia infiammatoria intestinale o stipsi
    16. Altre neoplasie nei 3 anni precedenti diverse da: carcinoma a cellule squamose o basali della pelle trattato terapeuticamente, carcinoma in situ della cervice, carcinoma della prostata organo-confinato o non metastatico trattato con antigene prostatico specifico negativo, carcinoma in situ della mammella dopo resezione completa o carcinoma superficiale della vescica a cellule transizionali
    17. Malattia concomitante non controllata, incluse a titolo esemplificativo ma non esaustivo infezioni attive in atto o malattie psichiatriche o situazioni sociali che, secondo il giudizio del medico curante, limiterebbero la compliance del paziente ai requisiti dello studio
    18. Nota sieropositività per il virus dell'immunodeficienza umano
    19. Infezione nota da virus dell'epatite A, B o C
    20. Pazienti gestanti o che allattano al seno
    E.5 End points
    E.5.1Primary end point(s)
    The primary efficacy variable for dosage selection is the percent
    reduction in spleen volume from baseline.
    The primary safety measure for dosage selection is the percentage of
    patients with CTCAE grade =3 cardiac AEs (Standardized MedDRA Query
    [SMQ]), CTCAE grade =3 hemorrhage AEs (SMQ), CTCAE grade =4
    thrombocytopenia toxicity (central laboratory based), or CTCAE grade =4
    anemia toxicity (central laboratory based).
    The primary efficacy variable for dosage selection is the percent
    reduction in spleen volume from baseline.
    The primary safety measure for dosage selection is the percentage of
    patients with CTCAE grade =3 cardiac AEs (Standardized MedDRA Query
    [SMQ]), CTCAE grade =3 hemorrhage AEs (SMQ), CTCAE grade =4
    thrombocytopenia toxicity (central laboratory based), or CTCAE grade =4
    anemia toxicity (central laboratory based).
    E.5.1.1Timepoint(s) of evaluation of this end point
    The primary endpoint is measured at Weeks 12 and 24.
    The primary endpoint is measured at Weeks 12 and 24.
    E.5.2Secondary end point(s)
    Other supportive measures for evaluation as part of the dose¿response
    relationship include: the percentage of patients who achieve at least
    35% reduction in spleen volume; % TSS reduction from baseline; and
    the percentage of patients with at least 50% reduction in TSS.
    All other safety data including AEs, death, and clinical laboratory
    measures will be used as supportive measures for evaluation of
    pacritinib dose-safety relationship.
    Other supportive measures for evaluation as part of the dose¿response
    relationship include: the percentage of patients who achieve at least
    35% reduction in spleen volume; % TSS reduction from baseline; and
    the percentage of patients with at least 50% reduction in TSS.
    All other safety data including AEs, death, and clinical laboratory
    measures will be used as supportive measures for evaluation of
    pacritinib dose-safety relationship.
    E.5.2.1Timepoint(s) of evaluation of this end point
    The secondary endpoint is measured at Weeks 12 and 24.
    The secondary endpoint is measured at Weeks 12 and 24.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response Yes
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other Yes
    E.8.1.7.1Other trial design description
    open
    open
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial3
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned8
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA21
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    France
    Germany
    Hungary
    Italy
    Spain
    Sweden
    United Kingdom
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months9
    E.8.9.1In the Member State concerned days15
    E.8.9.2In all countries concerned by the trial years1
    E.8.9.2In all countries concerned by the trial months9
    E.8.9.2In all countries concerned by the trial days15
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 50
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 55
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state10
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 40
    F.4.2.2In the whole clinical trial 105
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    The sponsor intends to allow patients to continue to receive pacritinib after completing the study if the patient and investigator feel they are benefitting from pacritinib treatment and if allowed by the governing regulatory agency.
    The sponsor intends to allow patients to continue to receive pacritinib after completing the study if the patient and investigator feel they are benefitting from pacritinib treatment and if allowed by the governing regulatory agency.feel you are benefitting from pacritinib treatment.¿
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2017-09-22
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2017-10-24
    P. End of Trial
    P.End of Trial StatusCompleted
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Apr 28 16:06:59 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA